Spots Global Cancer Trial Database for Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

Study Description

Brief Summary: This phase II trial studies the effect of venetoclax together with busulfan, cladribine, and fludarabine in treating patients with high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing stem cell transplant. Chemotherapy drugs, such as venetoclax, busulfan, cladribine, and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding venetoclax to the current standard of care stem cell transplant regimen of busulfan, fludarabine, and cladribine may help to control high-risk acute myeloid leukemia or myelodysplastic syndrome.

Detailed Description: Phase 2 Portion Primary Objective 1) To obtain preliminary evidence of efficacy as defined by 1-year progression free survival. Secondary Objectives To determine: 1. Safety of this regimen as per NCI toxicity criteria 2. Time to neutrophil and platelet engraftment 3. Incidence of acute and chronic GVHD 4. Relapse incidence 5. Non-relapse mortality 6. Overall survival 7. Graft versus host disease-relapse free survival (GRFS) Phase 3 Portion Primary Objective 1) To compare progression free survival between two arms Arm 1 Standard of Care: fludarabine + IV busulfan (FluBu) versus Arm 2 Experimental: Venetoclax + Fractionated busulfan, cladribine, and fludarabine Secondary Objectives To compare following between two arms 1. Safety of this regimen as per NCI toxicity criteria 2. Time to neutrophil and platelet engraftment 3. Incidence of acute and chronic GVHD 4. Relapse incidence 5. Non-relapse mortality 6. Overall survival 7. Graft versus host disease-relapse free survival (GRFS)

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Contact Details

Useful links and downloads for this trial